Skip to main content

Table 3 Biochemical markers in rheumatoid arthritis clinical trials: selected studies evaluating MRI-based measures and biochemical markers

From: Biochemical markers of ongoing joint damage in rheumatoid arthritis - current and future applications, limitations and opportunities

Reference N Design/study if named Image modality Markers evaluated Results
[180] 84 Longitudinal analysis MRI and X-ray sCTX-I and uCTX-II sOPG, sYKL-40, sCOMP and sMMP-3 sCTX-I and uCTX-II were significant predictors of progressive joint destruction
[181] 377 Cross-sectional analysis MRI CTX-II Correlation of uCTX-II with BME
[155] 98 Cross-sectional analysis MRI COMP, MMP-3, CRP COMP was elevated in those with bone erosions
[182] 72 Longitudinal analysis MRI IL-6, VEGF, YKL-40, CRP and ESR Only IL-6 correlated with disease progression
  1. BME, bone marrow edema; COMP, cartilage oligomeric protein; CRP, C-reactive protein; CTX-I, C-terminal telopeptide of collagen type I; CTX-II, C-terminal telopeptide of collagen type II; ESR, erythrocyte sedimentation rate; MMP, matrix metalloproteinase; OPG, osteoprotegerin; s, serum; u, urinary; VEGF, vascular endothelial growth factor.